Medically reviewed by Drugs.com. Last updated on Jan 19, 2021.
Applies to the following strengths: 620 mcg/2.48 mL; 750 mcg/3 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Osteoporosis
20 mcg subcutaneously once a day into the thigh or abdominal wall
-Duration of Therapy: Lifetime use greater than 2 years should only be considered if fracture risk remains high
-This drug is indicated for men and women as described below who are at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
-High fracture is defined as history of osteoporotic fracture or multiple risk factors for fracture.
-Supplemental calcium and vitamin D should be taken if daily dietary intake is inadequate.
-For the treatment of postmenopausal women with osteoporosis
-To increase bone mass in men with primary or hypogonadal osteoporosis
-For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid (equivalent to prednisone 5 mg/day or greater)
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
-Hypersensitivity to the active ingredient or any product ingredients; hypersensitivity reactions have included angioedema and anaphylaxis
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-For subcutaneous administration only; not for IM or IV use
-Administer subcutaneously once a day into thigh or abdominal region
-Patients should be instructed on proper administration technique
-Initial doses of this drug should be administered in settings where patient can sit or lie down if symptoms of orthostatic hypotension occur
-Store under refrigeration 2 to 8 degrees C (36 to 46 degrees F) at all times except when administering product; limit time out of refrigerator
-Once opened, can be used for up to 28 days; discard after 28 days
-Do not freeze; do not use if it has been frozen
-Store with cap on to protect from physical damage and light
-Supplemental calcium and vitamin D should be given if dietary intake is inadequate.
-In postmenopausal women with osteoporosis, this drug has been shown to reduce the risk of vertebral and nonvertebral fractures.
-Use for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture as there is limited data assessing the risk of osteosarcoma beyond 2 years of use.
-Observe for orthostatic hypotension, especially with first few doses
-Consider measuring urinary calcium excretion in patients with active or recent urolithiasis
-Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
-Patients should be aware that an increased incidence of osteosarcoma has been observed in rat studies, but observational human studies have not shown this risk for use up to 2 years.
-Patients should be instructed to notify their healthcare provider if they develop persistent symptoms of hypercalcemia.
Frequently asked questions
More about teriparatide
- Side Effects
- During Pregnancy or Patient Tips
- Drug Interactions
- Pricing & Coupons
- En Español
- 132 Reviews
- Drug class: parathyroid hormone and analogs
- Other brands
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.